In today’s ACT Brief, we examine how legacy workflows pull community clinics away from patient care, why medical writing capacity depends on training rather than technology, and how an antiviral aims to prevent COVID-19 after exposure
News|Podcasts|October 7, 2026
ACT Brief: FDA Transparency Roadmap, Radiopharmaceutical Trial Operations, and AI-Powered Enrollment Prediction
Author(s)Andy Studna, Senior Editor
In today's ACT Brief, we examine the FDA's multi-domain transparency priorities, why radiopharmaceutical trials need redesigned infrastructure, and how AI can make enrollment more predictable.
This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.
- In a
new transparency roadmap , the FDA outlined fiscal year 2026 milestones and fiscal year 2027 priorities across five areas: CRL disclosure, investigational and marketing application lifecycle transparency, new approach methodologies and novel biomarkers, patient-centered labeling, and compliance and inspectional records. The agency also formalized a memorandum of understanding with the SEC in August 2026 to establish regular information sharing between the two agencies on FDA-regulated products and firms for use in regulatory and enforcement activities. - In a
new contributed article , Kavita Gaadhe examined why radiopharmaceutical trials are exposing a broader challenge for clinical development: scientific innovation can advance only as fast as the infrastructure, data, and cross-functional decisions required to deliver it. With the radiopharmaceuticals market projected to grow eight to ten percent annually to nearly 14 billion dollars by 2033, trial success increasingly rests on three interconnected pillars beyond the molecular design. - In a
new podcast from Pharmaceutical Executive , Matt Walz, CEO of Trialbee, explored how AI is delivering practical gains in enrollment planning and discussed its future potential in making clinical development's biggest bottleneck more predictable. He outlined how AI applied to internal workflows differs fundamentally from AI-driven decision-making based on real-world data, where bias concerns require different governance and oversight approaches.
That's all for today's ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.
Related to this article
In today’s ACT Brief, we examine how cost barriers and site infrastructure limit participation in community trials, why endpoints should reflect what patients actually experience, and how the FDA expanded a prostate cancer combination to an earlier treatment setting.
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
In today’s ACT Brief, we examine how AI is moving into continuous clinical operating models, how trust is built into oncology real-world evidence, and how the FDA approved a self-administered option for thyroid eye disease.
In today’s ACT Brief, we examine who decides what trials measure, how designing for human thinking improves site execution, and how the FDA extended an immunotherapy to a new bladder cancer population.
In Episode 3 of The Human Side of Clinical Trials, hosts Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., speak with Jason Riis, PhD, CEO and chief behavioral scientist at Behavioralize, about why a well-written protocol doesn’t always translate into consistent execution, and how designing for the way people actually think and learn can reduce site burden and the need for costly unlearning.
In today’s ACT Brief, we examine what it will take to scale EHR-to-EDC connections for real-time trials, how the FDA is reimagining rare disease drug development, and why oncology real-world evidence still faces persistent data barriers.
Medical writing capacity pressure is fundamentally a talent development problem, not a technology problem, since hybrid resourcing and AI cannot substitute for the experienced judgment needed to review AI output and mentor the next generation of writers.
Trending on Applied Clinical Trials Online
1
How Much of the Community Participation Gap Is About Infrastructure, Not Willingness?
2
Closing the Medical Writing Capacity Gap: Why Training Beats Technology
3
Measuring What Matters: Realigning Clinical Endpoints with Patient Reality
4
Clinical Trials Do Not Have a Data Problem, They Have a Decision-Readiness Problem
5